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Abstract: Tryptophan-2,3-dioxygenase (TDO) is one of the key tryptophan-catabolizing enzymes 
with immunoregulatory properties in cancer. Contrary to expectation, clinical trials showed that 
inhibitors of the ubiquitously expressed enzyme, indoleamine-2,3-dioxygenase-1 (IDO1), do not 
provide benefits in melanoma patients. This prompted the hypothesis that TDO may be a more 
attractive target. Because the promoter of TDO harbors glucocorticoid response elements (GREs), 
we aimed to assess whether dexamethasone (dex), a commonly used glucocorticoid, modulates 
TDO expression by means of RT-PCR and immunofluorescence and function by assessing cell pro-
liferation and migration as well as metalloproteinase activity. Our results show that, in SK-Mel-28 
melanoma cells, dex up-regulated TDO and its downstream effector aryl hydrocarbon receptor 
(AHR) but not IDO1. Furthermore, dex stimulated cellular proliferation and migration and poten-
tiated MMP2 activity. These effects were inhibited by the selective TDO inhibitor 680C91 and en-
hanced by IDO1 inhibitors. Taken together, our results demonstrate that the metastatic melanoma 
cell line SK-Mel-28 possesses a functional TDO which can also modulate cancer cell phenotype di-
rectly rather than through immune suppression. Thus, TDO appears to be a promising, tractable 
target in the management or the treatment of melanoma progression. 
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1. Introduction 
L-tryptophan (Trp) is an essential amino acid that plays important roles in protein 
synthesis as well as the biosynthesis of melatonin, serotonin, and nicotinamide adenine 
dinucleotide (NAD+) [1]. The role of Trp catabolism in cancer biology has been receiving 
increased interest due to its implication in cancer immune evasion [2]. Indoleamine-2,3-
dioxygenase-1 (IDO1) and tryptophan-2,3-dioxygenase (TDO) are the main enzymes 
within the first and rate-limiting step of the kynurenine pathway (KP) of Trp catabolism. 
Most Trp are catabolized by IDO1, which is ubiquitously expressed and can be induced 
by interferon gamma (IFN-γ) [3]. Interestingly, IDO1 has been widely demonstrated to 
possess immunosuppressive functions, which are established to correlate with poor sur-
vival in various cancer patients [2] (Figure 1). 
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Figure 1. Tryptophan catabolism and kynurenine pathway. Indoleamine-2,3-dioxygenase (IDO1) 
and tryptophan-2,3-dioxygenase (TDO) pathways control T cell and Treg responses. IDO1—and 
TDO but to a lesser extent—are expressed on professional antigen presenting cells and tumor cells 
and are critical in immune regulation of cancers, infections, and inflammation. 
Despite all efforts of early diagnosis, metastatic melanoma continues to have a poor 
prognosis [4]. In recent years, a better understanding of the role of the immune system in 
cancer has led to the approval of several immunotherapies using monoclonal antibodies 
against immune checkpoints, such as ipilimumab (anti CTLA-4) as well as nivolumab and 
pembrolizumab (anti PD-1) [4]. Unfortunately, only specific subgroups of patients re-
sponded to these immunotherapies, pointing out IDO1 as a further ideal candidate [3]. It 
was indeed reported that reduced serum tryptophan concentrations could be predictive 
markers for melanoma [5]. Although selective and potent IDO1 inhibitors have shown 
promising results in experimental models of cancer [6], their benefit in melanoma patients 
has not been completely elucidated. Indeed, in a phase 3 randomized, double blind study, 
ECHO-301/KEYNOTE-252, a selective IDO1 inhibitor, epacadostat 100 mg twice daily, 
plus pembrolizumab did not improve progression-free survival or overall survival com-
pared with placebo plus pembrolizumab in patients with unresectable or metastatic mel-
anoma [7]. Due to the uncertain benefit of IDO1 inhibition as a strategy to enhance im-
mune checkpoints activity, and since approximately 35% of tumor cancer cell lines express 
TDO [8], this enzyme became a very attractive target in cancer immunotherapy [9]. 
TDO is physiologically expressed in the liver where it plays a critical role in regulat-
ing Trp levels. Following some stimuli, however, TDO’s expression can be detected in 
several organs, including testis [10], placenta [11], and brain [12]. More recent studies have 
pointed out the relevance of TDO in some cancers, namely malignant glioma, melanoma, 
bladder cancer, and triple-negative breast carcinoma [13,14]. Indeed, TDO appears to be 
constitutively expressed in these cancer cells, and its upregulation has been intimately 
associated with the ability of tumor cells to evade immune surveillance [15]. Therefore, 
TDO may represent an attractive target, especially when IDO1 does not account for con-
stitutive Trp catabolism [8,16]. 
The glucocorticoid (GC) derivative dexamethasone (dex) is routinely used as a co-
medication in cancer therapy to ameliorate some side effects of chemotherapeutic agents 
[17,18]. In hematological malignancies, particularly in multiple myeloma, dex is part of all 
chemotherapy protocols, owing to its strong apoptosis-inducing effects [19]. However, 
GCs could also inhibit chemotherapy-induced tumor cell’s apoptosis in in vitro and in 
vivo experimental models as well as in freshly obtained surgical specimens of some tu-
mors, including melanoma [20]. 
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The effects of dex on tumor cell growth remain inconclusive, likely due to the many 
factors involved, including dose and cell context [21,22]. Therefore, to clearly determine 
the clinical relevance of GCs, their effects on the malignant phenotype ought to be eluci-
dated. Since TDO promotor possesses glucocorticoid response elements (GREs) [23], a role 
for TDO in tumor biology and progression has attracted attention, especially in the context 
of melanoma. 
Based on these considerations, this study was undertaken to better characterize 
TDO/KP in SK-Mel-28, a human melanoma cell line. We previously demonstrated that 
TDO is constitutively expressed in these cells and that it directly regulates their prolifera-
tion [24]. However, the effect of dex on TDO expression and function remained unclear. 
Here, we seek to determine this role in order to better delineate glucocorticoid’s effects on 
melanoma cells. 
2. Results 
2.1. Dexamethasone Increased TDO and AHR Expression 
Since TDO promotor harbors GREs, we wished to determine the effect of dexame-
thasone (dex) on its expression in SK-Mel-28 cells. Our results show that dex indeed in-
creases TDO mRNA (TDO2) expression in concentration (data not shown) and time-de-
pendent manners. The maximal effect was observed after six hours of treatment with 25 
µM of dex (Figure 2A). Immunofluorescence analysis further confirmed the increase in 
protein levels of TDO in response to dex (Figure 2B). 
 
Figure 2. Dexamethasone (dex) increases mRNA and protein expression of TDO. (A) Cells were treated with dex (25 µM) 
for different time points. RT-PCR shows time-dependent increase in mRNA of TDO2. Data are plotted as mean ± SEM (n 
= 8, ** p < 0.01 vs. control). (B) Cells treated without (ctrl) or with dex (25 µM) for 6 or 24 h, then subjected to immunoflu-
orescence, TDO (green fluorescence), nuclei (blue). Representative photomicrographs at 40× magnification are shown. 
Scale bar 20 µm. 
Given the influence of IDO1 on melanoma’s malignant phenotype, we next aimed to 
determine its expression in SK-Mel-28. Electrophoresis of the amplified and purified tar-
get show that IFN-γ (50 ng/mL) but not dex (25 µM) increased expression of IDO1 (Figure 
3A). This was further confirmed by real-time PCR (Figure 3B) and immunofluorescence 
(Figure 3C). Interestingly, although IDO1 mRNA levels were almost undetectable, an IDO 
inhibitor, 1-MT, significantly enhanced dex-induced TDO2 upregulation (Figure 3D). This 
may suggest that SK-Mel-28 cells could use TDO as principal enzyme for the activation of 
the KP. 




Figure 3. Modulation of IDO1 and TDO2 by interferon gamma (IFN-γ) or dex. (A) Cells were treated 
without (ctrl) or with dex (25 µM) or with IFN-γ (50 ng/mL) for 24 h. Total RNA was then isolated, 
and RT-PCR-generated cDNA of IDO1 was subjected to agarose gel electrophoresis. (B) Cells were 
treated without (ctrl) or with dex (25 µM) or with IFN-γ (50 ng/mL) for 24 h. Total RNA was then 
isolated, and real time PCR was performed. Data represent mean ± SEM, (n = 4; *** p < 0.001 vs. 
control unstimulated (ctrl) cells). (C) Cells were treated without (ctrl) or with dex (25 µM) or with 
IFN-γ (50 ng/mL) for 24 h, followed by immunofluorescence for IDO1 expression (IDO1: green; 
nuclei: blue). Representative photomicrographs at 40× magnification are shown. Scale bar 20 µm. 
(D) Cells were treated with dex (25 µM) in the presence or absence of 40 µM 1-MT, an IDO inhibitor. 
Real-time PCR results for TDO2 expression are shown. Data plotted represent mean ± SEM. Increase 
over dex effect (n = 6; ## p < 0.01 vs. dex alone). 
Among the downstream effectors of KP, the aryl hydrocarbon receptor (AHR) repre-
sents an important target. Our results show that treatment with dex upregulated mRNA 
and protein levels of AHR (Figure 4A,B). Interestingly, this effect was rapid, as it was 
significantly increased within 3 h of stimulation with dex (Figure 4A). This increase is not 
sustained since the level of AHR after 24 h of dex does not seem to cause an appreciable 
change over basal level (Figure 4B). This is likely due to the fact that dex accelerates both 
ligand-dependent and ligand independent AHR protein degradation in a GR-dependent 
manner [25]. 




Figure 4. Dex modulates aryl hydrocarbon receptor (AHR) expression. (A) Cells were treated without (ctrl) or with dex 
(25 µM) for 3 and 6 h. Total RNA was then isolated, and real time PCR was performed. Data represent mean ± SEM, (n = 
5; ** p < 0.001 vs. control unstimulated (ctrl) cells; # p < 0.05 vs. dex 3 h. (B) Cells were treated without (ctrl) or with dex (25 
µM) for 3, 6, and 24 h followed by immunofluorescence for AHR expression (AHR: green; nuclei: blue). Representative 
photomicrographs at 40× magnification are shown. Scale bar 20 µm. 
2.2. Dexamethasone Stimulates SK-Mel-28 Proliferation via TDO and PI3K/Akt 
Because TDO is involved in the regulation of SK-Mel-28 growth [24], and since dex 
induced TDO up-regulation, we then wished to determine whether dex stimulates SK-
Mel-28 proliferation via TDO. Our results show that dex significantly and concentration-
dependently increased SK-Mel-28 proliferation (Figure 5A). The maximal effect was ob-
tained with 25 µM, which caused a 48.4 ± 9% increase in cell duplication compared to 
control unstimulated cells. Dex-promoted cell proliferation appears to be dependent on 
glucocorticoid receptors and on increased transcriptional activity, since it was abolished 
by the steroid receptor antagonist RU486 (1 µM) and by actinomycin-D (10 nM), a DNA-
dependent RNA synthesis inhibitor (Figure 5B). 




Figure 5. TDO mediates dex-induced SK-Mel-28 proliferation. (A) Cells were treated without (ctrl) or with increasing 
concentrations of dex for 48 h. Data are plotted as percent of control. Mean ± SE (n = 7; * p < 0.05, *** p < 0.001 versus ctrl). 
(B–D) Cells were treated with dex (25 µM) alone (dex) or in presence of (B) RU486 (1 µM) or actinomycin D (10 nM) or 
(C) 680C91 (40 µM) and FGF2 (10 ng/mL) or (D) 1-MT (40 µM) or epacadostat (1 µM), and proliferation was assessed. Data 
are plotted as mean ± SE (n = 7; # p < 0.05, ### p < 0.001 vs. dex alone). 
To delineate the mechanisms underlying the proliferative effect of dex, cells were 
pretreated for 15 min with 680C91 (40 µM), a selective TDO inhibitor, followed by dex (25 
µM). Interestingly, 680C91 significantly hampered cell proliferation by 41.2 ± 7.1%, with-
out affecting either cell viability [24] or cell duplication in response to FGF2 (Figure 5C). 
Furthermore, inhibition of IDO1 with 1-MT or epacadostat, a newer IDO1 inhibitor, po-
tentiated dex-induced cell proliferation (Figure 5D). 
It is well-documented that dex activates mitogenic pathways such as the Akt and the 
MAPK cascades in normal [26,27] and tumor cells [21]. Here, we assessed whether dex 
indeed activates these pathways. Treatment with 25 µM dex stimulated Akt phosphory-
lation within 3 h, and this effect was partially but significantly inhibited by 680C91 (Figure 
6A,B), while ERK1/2 was not activated (data not shown). The dex-activated PI3K/Akt 
pathway appears to mediate cell proliferation, since inhibiting this pathway did impair 
SK-Mel-28 proliferation. Consistently, U0126, an MEK inhibitor, did not significantly alter 
cell proliferation (Figure 6C). 




Figure 6. Dex activates Akt in SK-Mel-28 cells. (A) Cells were treated with dex for different durations (3, 6, or 12 h). Western 
blotting for phosphorylated Akt and β-tubulin. (B) Cells were stimulated with 25 µM dex alone (dex) or in presence of 40 
µM 680C91 (+680C91) for 3 h (* p < 0.05, vs. ctrl; # p < 0.05 vs. dex alone). (C) Cells were treated with dex alone (dex) or co-
treated with LY294002 (5 µM) or U0126 (10 µM), Akt and MEK inhibitors, respectively, and proliferation assessed. Data 
are plotted as mean ± SE (n = 3; # p < 0.05, vs. dex alone). 
2.3. Dexamethasone Stimulates SK-Mel-28 Migration 
Wound healing assay was employed to examine the effect of dex on cell migration. 
Our results show that, compared to control cells (1% fetal bovine serum (FBS)), dex-stim-
ulated cells exhibited significantly higher migratory capacity (Figure 7A,B). This effect 
was further potentiated by epacadostat, an IDO1 inhibitor. Furthermore, dex-induced mi-
gration was mediated by its cognate receptors since pre-treatment with RU486 abolished 
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dex-induced cell migration. Interestingly, the TDO inhibitor 680C91 delayed dex effect 
(Figure 7), probably due to dex-induced TDO transcription (Figure 2). 
 
Figure 7. Dex stimulates SK-Mel-28 cell migration. (A,B) Scratched monolayer was treated with 25 µM dex for 24 h in 
absence (dex) or in presence of RU486 (1 µM), 680C91 (40 µM), epacadostat (1 µM), or actinomycin-D (10 Nm). (A) Pho-
tomicrographs of the wound were taken, and representative images are shown (4×). (B) Quantitative measure of the 
wound’s width. Data represent mean ± SEM of the migration rate (n = 5; ** p < 0.01, *** p < 0.001 vs. control unstimulated 
cells (ctrl); # p < 0.05, ### p < 0.001 vs. dex alone. (C,D) Chemotaxis of SK-Mel-28 cells stimulated with 25 µM dex for 24 h 
in absence (dex) or in presence of RU486 (1 µM), 680C91 (40 µM), epacadostat (1 µM) or actinomycin-D (10 nM). (C) 
Photomicrographs of the migrated cells were taken, and representative images are shown (20×). (B) Quantitative measure 
of cell chemotaxis. Data represent mean ± SEM of migrated cells (n = 4; * p < 0.05, ** p < 0.01 vs. control unstimulated cells 
(ctrl); # p < 0.05 vs. dex alone. 
Cell chemotaxis was also assessed by means of the Boyden chamber assay. Data show 
that dex significantly stimulated SK-Mel-28 cell chemotaxis compared to control unstim-
ulated cells (1% FBS, Figure 7C,D). This effect was further potentiated by epacadostat and 
was impaired by RU486, actinomycin-D, and the TDO inhibitor 680C91 (Figure 7C,D). 
2.4. Dexamethasone Effect on MMP2 Activity 
Invasion is a hallmark of malignant phenotype of cancer cells, including melanomas. 
Matrix metalloproteinases (MMPs) are major drivers of cellular invasion. Among these 
MMPs, MMP2 seems to be the most abundantly secreted by SK-Mel-28 [28]. Thus, we 
measured MMP2 expression and activity in conditioned media of SK-Mel-28 cells stimu-
lated with dex. Gelatin zymography of control supernatants showed constitutive release 
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of the latent forms of MMP2 visualized as a band at 72 kDa (Figure 8). Dex significantly 
stimulated the release of MMP2 within 48 h and induced its activation, revealed by the 
appearance of the band at 62 kDa (Figure 8). This increase in MMP2 activity is significantly 
diminished by RU486 and by 680C91 (Figure 8). No effect of dex on MMP9 was observed 
(data not shown). 
 
Figure 8. Gelatin zymography for matrix metalloproteinases (MMP2) production in response to dex 
alone or in presence of epacadostat (1 µM) or 680C91 (40 µM) or RU486 (1 µM). Results are reported 
as mean ± SEM of band densitometry, n = 5. * p < 0.05 vs. latent MMP2 and # p < 0.05 vs. activated 
MMP2 of control unstimulated cells (ctrl); ° p < 0.05 vs. dex alone. 
3. Discussion 
In addition to playing a key role in the KP, TDO appears to have a vital role in cancer 
cell’s ability to evade the immune system [29]. TDO harbors GREs in its promoter, thus 
prompting the speculation that dex and other glucocorticoids (GCs) may regulate its ex-
pression and hence may affect tumorigenesis. Indeed, different reports highlighted a role 
for dex in lymphocytic malignancies as well as epithelial cell-derived cancers. In the for-
mer, dex and other GCs are routinely used to induce apoptotic cell death. Conversely, in 
solid tumors, GCs, mostly dex, are often used at high doses to minimize side effects of 
chemotherapeutic agents [19,30]. Furthermore, several reports suggest that GCs stimulate 
expression of anti-apoptotic genes and hence antagonize the ability of cytotoxic drugs to 
successfully induce cell death [31]. Moreover, in vivo studies on stress-induced GCs sug-
gest a positive relationship between GCs and melanoma progression [32,33]. 
To this end, we investigated the effects of dex on both TDO expression in SK-Mel-28 
cells and on proliferation and migration of these cells. The present paper shows, for the 
first time, that dex up-regulated both mRNA and protein levels of TDO. Dex also up-
regulated AHR, a ligand-activated transcription factor. AHR is activated by KP metabo-
lites, such as kynurenine, and is involved in cell proliferation, inflammation, immunity, 
and regulation of the melanogenic pathway [34–36]. Indeed, AHR diminishes the efficacy 
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of novel immunotherapies by potentiation of the production of antibodies that block im-
munoregulatory molecules and by suppressing apoptosis of dormant melanoma cells [37]. 
Moreover, in triple-negative breast cancer cells, the TDO–AHR signaling axis facilitates 
anoikis resistance and metastasis [13] and stimulates cell migration [38]. 
Based on these data, it was tempting to investigate the effects of dex on SK-Mel-28 
proliferation and migration in order to better assess the potential involvement of TDO in 
those effects. Here, we showed that dex enhanced proliferative and migratory capacities 
of SK-Mel-28 cells. We also showed that these effects depend on GR activation, rely on 
increased transcriptional activity, and are mediated by TDO. We also showed that dex-
induced MMP2 activity is also mediated by GR and TDO. Conversely, MMP9 was unde-
tected, in line with previous data [28]. Our results are consistent with previous reports 
showing that dex and prednisolone stimulate proliferation and survival of many tumor 
cells, both in vitro and in vivo, by activating GRs and Akt pathway [21]. Contextually, 
Chaudhuri et al. [39] described a detrimental effect of dex in a young patient with meta-
static melanoma. This patient received dex 8 mg/os four times a day for 10 days. Although 
the patient symptomatically improved, it appears that the subcutaneous metastasis rap-
idly increased, exacerbating the disease. Moreover, metastatic nodule biopsy demon-
strated a specific cytosol receptor for glucocorticoid with a KD of 1.8 × 10−9 M. Other evi-
dence confirms that glucocorticoids significantly promote adhesion, migration, invasion 
of melanoma cells in vitro, and lung metastasis in vivo [40]. These effects were mediated 
by Akt, ROCK1/2, and tissue inhibitors of MMP-2 (TIMP2). In addition, dex is known to 
promote adhesion and survival of human and murine melanoma cell lines through fibron-
ectin regulation and increased chemo-resistance to anticancer agents such as cisplatin [41]. 
Indeed, prolonged treatment of melanoma cells with dex results in the formation of a cell 
subline resistant to dex’s growth inhibitory action by virtue of an acquired phenotype of 
constitutive activation of PI3K. Not surprisingly, PI3K is considered one of the key factors 
that regulate cell resistance to dex [42]. Dex was also reported to exhibit antiproliferative 
and proapoptotic effects in other cells such as HT168 and HT168-M1 cell lines [22]. These 
seemingly contradictory results may be explained by the fact that higher dex concentra-
tions were used. Nonetheless, no data were indeed reported on possible TDO expression 
and function on HT168 and HT168-M1 melanoma cell lines. Based on our present results, 
it is clear that SK-Mel-28 cells physiologically express TDO whose expression and function 
are modulated by dex. 
Since IDO1 is the principal enzyme of the KP in normal and tumor tissues, we studied 
its expression in SK-Mel-28 in response to dex. However, this melanoma cell line did not 
show IDO1 mRNA expression in control unstimulated cells, and immunofluorescence 
showed a faint IDO reactivity which was only upregulated in response to IFN-γ, as re-
ported for other tumor cells [43]. However, when IDO1 was pharmacologically inhibited, 
dex-induced migration and proliferation were significantly increased, indicating that, in 
SK-Mel-28, the KP is driven by TDO and may be amplified when IDO1 is impaired. This 
may be in line with other reports [16] showing that TDO/KP could be involved in cancer 
biology, particularly when IDO1 does not account for the constitutive Trp catabolism. 
Among the possible intracellular pathways activated by dex/TDO in SK-Mel-28, 
PI3K/Akt seems to be involved in dex-induced phenotypic changes. Indeed, we showed 
that dex stimulated Akt phosphorylation, which was critical for dex-induced prolifera-
tion. This is in line with another study which showed that T-acute lymp hoblastic leuke-
mia (T-ALL) cells acquire resistance to dex-mediated killing through abnormal activation 
of Akt, resulting in inhibition of the FoxO3a/Bim pathway [44]. Furthermore, dex and 
prednisolone were reported to increase in vitro survival in 21/65 samples from glucocor-
ticoid-resistant primary leukemias. Importantly, dex-induced proliferation was mediated 
by PI3K/AKT and p38 mitogen-activated protein kinase [21]. Moreover, dex modulated 
trastuzumab-induced cell growth inhibition through the restoration of trastuzumab-in-
duced Akt suppression in BT-474 breast cancer cells [45]. All these observations suggest 
PI3K/Akt as the major pathway involved in pro-survival and proliferative effects of dex. 
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Therefore, the metastatic melanoma cell line SK-Mel-28 possesses a functional TDO 
which regulates SK-Mel-28 proliferation and migration in response to dex. It is well 
known that GCs are able to promote tumor onset and progression by virtue of their sys-
temic immunosuppressive effects. However, GCs can have direct effects on proliferation, 
migration (our present data), and survival of tumor cells [21]. As shown elsewhere, GCs 
can also potentiate chemoresistance to therapy through regulation of genes involved in 
cancer progression [46,47]. 
Clinical evidence highlights a detrimental effect of systemic steroids during immu-
notherapy [48]. For instance, it was recently shown that there is an association between 
immune-related adverse events (irAEs) and outcomes in patients with stage III melanoma 
treated with adjuvant pembrolizumab within the KEYNOTE-054 trial [49]. Similarly, use 
of systemic corticosteroids during anti-PD1 nivolumab therapy was associated with 
poorer outcomes in non-small-cell lung cancer patients [48,50,51]. Hence, targeting gluco-
corticoids to increase cancer immunotherapy efficacy is an intriguing strategy. In this con-
text, it is important to note that glucocorticoid-induced tumor necrosis factor receptor-
related protein (GITR) could be an additional therapeutic target involving corticosteroid 
pathway. GITR is a receptor on T cells capable of inhibiting T cell receptor-induced apop-
tosis [52]; its natural ligand, GITRL, is part of the TNF superfamily, and it is expressed by 
a variety of cells, including mature and immature dendritic cells [52,53]. The GITR-GITRL 
interplay can reverse the suppression by Treg cells while stimulating effector T cells [52,54]. 
Therefore, modulation of GITR is involved in the anti-inflammatory action of corticoster-
oids, making it a therapeutic target in immune regulation [52]. Preliminary results of a 
humanized monoclonal antibody (TRX518) that triggers GITR, given as monotherapy to 
patients with refractory solid tumors (including melanoma), demonstrated that TRX518 
reduces circulating and intratumoral Treg cells to a similar extent, providing an easily eval-
uable biomarker of anti-GITR activity [55]. More recently, an open-label, phase 1/2a study 
evaluated the effect of GITR-agonist IgG1 monoclonal antibody, BMS-986156, with or 
without nivolumab, on 292 patients with advanced solid tumors [56]. Results of this trial 
showed that BMS-986156 exhibits a manageable safety profile, and its combination with 
nivolumab is safe and efficacious, much like nivolumab monotherapy. Despite these en-
couraging data, further evidence in this field is still needed. 
In conclusion, given the uncertain efficacy of IDO1 inhibitors together with immune 
checkpoint inhibitors in advanced melanoma and, based on our current results, demon-
strating a direct effect of dex on TDO expression and function in human SK-Mel-28 mela-
noma cell line, it becomes of increasing importance to better characterize the involvement 
of the TDO pathway in melanoma tumorigenesis. It is also mandatory to elucidate the 
effects of GCs on solid tumors, including melanoma. 
4. Materials and Methods 
4.1. Cell Culture 
SK-Mel-28 (ATCC, Manassas, VA, USA), a human metastatic melanoma cell line, was 
grown in high D-glucose DMEM, with 10% (v/v) heat inactivated fetal bovine serum (FBS 
Defined Hyclone; ThermoFisher Scientific, Waltman, Massachusetts, USA), 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 2 mmol/L glutamine in a humidified atmosphere 
with 5% CO2 in air. The culture medium was changed every 2 days. 
4.2. RT-PCR and Real Time PCR 
Total RNA was isolated using TRI Reagent and quantified spectroscopically with a 
NanoDrop (ThermoFisher Scientific). One µg of RNA was used for the reverse transcrip-
tion reaction with Prime Script RT reagent Kit with gDNA eraser (Takara, Otsu, Japan), 
and the cDNA samples obtained were amplified with specific primers described below. 
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Qualitative PCR for IDO1 was performed using Wonder Taq Thermostable DNA pol-
ymerase (EuroClone, Milan, Italy). Primers for IDO1 were: fw 5′-AGTTCTGG-
GATGCATCACCA-3′and rev 5′-TGATCGTGGATTTGGTGAAA-3′. PCR amplification 
comrpised 40 cycles of initial denaturation at 95 °C for 1 min, denaturation at 95 °C for 15 
s, annealing at 53 °C for 15 s, and extension at 72 °C for 30 s, followed by 5 min at 72 °C, 
using 2720 Thermal Cycler Applied Biosystem (ThermoFisher Scientific). Due to unde-
tectable cDNAs, they were concentrated combining four samples (800 ng), purified with 
QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer 
instructions, and separated by 1.8% agarose electrophoresis. 
Quantitative real-time PCR (qRT-PCR) was carried out using SYBR Premix Ex Taq 
(Takara) according to the manufacturer instructions on a Rotorgene RG-3000A cycle sys-
tem (Qiagen) platform. Primer sequences were the following: TDO2 fw: 5′-
CTTATCTCCAGCATCAGGCTTCCAGAGT-3′ and rev: 5′-GGAG-
TTCTTTCCAGCCATGCCTCC-3′ [24], IDO1 amplification fw: 5′-AGTTCTGG-
GATGCATCACCA-3′ and rev: 5′-CAGTTTCTTGGAGAGTTGGCA-3′ and AHR amplifi-
cation fw: 5′-CAAATCCTTCCAAGCGGCATA-3′ and rev: 5′-CGCTGAGCCTAA-
GAACTGAAA-3′. 
qRT-PCR amplification of 18 s ribosomal mRNA was used as a normalizer. 18 s am-
plification fw: 5′-ATTAAGGGTGTGGGCCGAAG-3′ and rev: 5′-GGTGATCACAC-
GTTCCACCT-3′. 
The cycle was set at 95 °C for 5 s, 55 °C for 30 s, and 72 °C for 30 s, repeated 35 times. 
Quantitative real-time polymerase chain reaction data analysis was accomplished with 
delta delta CT method. 
4.3. Cell Proliferation 
Cell proliferation was quantified by total DNA/well via a fluorescent dye (Cell pro-
liferation kit, Invitrogen, ThermoFisher Scientific) [57]. Briefly, cells were plated on flat-
bottom 96-multiwell plates and allowed to adhere overnight. Following a 24 h starving 
condition, cells were stimulated with increasing dex concentrations with or without sev-
eral inhibitors: the TDO selective inhibitor, 680C91 (40 µM), or the MEK inhibitor, UO126 
(10 µM), or the PI3K inhibitor, LY294002 (10 µM). After 48 h, 50 µL of dye binding solution 
were added to each microplate well and incubated at 37 °C for 45 min. Fluorescence in-
tensity was read using a fluorescence microplate reader with excitation at ~485 nm and 
emission detection at ~530 nm. 
4.4. Chemotactic Assay 
Cell migration was assessed with the modified Boyden chamber (48-multiwell plates; 
Neuroprobe, Gaithersburg, MD, USA) as previously reported [58]. Briefly, 1% fetal calf 
serum (FCS)-containing medium alone (control) or supplemented with 25 µM dex was 
added to the lower wells, while 20 × 104 cells were seeded into the upper wells without or 
with RU486, 680C91, or actinomycin D and incubated at 37 °C for 24 h. Methanol-fixed 
cells were stained with Diff-Quik (Dade Behring, Dudingen, Switzerland), and cell migra-
tion was measured by microscopic evaluation of the number of cells moved across the 
filter in ten randomly selected fields at magnification 400×. Each experimental point was 
measured in triplicate. 
4.5. Wound-Healing Assay 
Cells were cultured in 24-well plates, and after they reached 95% confluence, a 
straight cell-free wound was made by manual scratching using a sterile 1000 µL pipette 
tip. Cells were washed with PBS twice to eliminate any cellular debris, and a fresh me-
dium was added, which served as the negative control (1% FBS, control time 0 h). Cells 
were then stimulated with 25 µM dex alone or in the presence of inhibitors. After 24 h, 
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cells migrated into the wounded area were visualized and photographed using an in-
verted light microscope. The area covered by cells was calculated with Image J (version 
1.46) software, and results are reported as percent of migration rate, calculated using the 
formula: 
Migration rate (%) = (Area time 0 h − Area time 24 h/Area time 0 h) × 100. 
4.6. Western Blotting Analysis 
SK-Mel-28 cells were lysed in a Triton® X-100 lysis buffer, pH 7.4, followed by a cen-
trifugation at 14,000× g rpm for 10 min at 4 °C [57]. Cell lysate was run on 10% SDS-poly-
acrylamide gel electrophoresis, blotted onto PVDF membrane (Merck-Millipore, Darm-
stadt, Germany), and immunostained with anti-phospho Akt (1:1000; Cell Signaling Tech-
nology, MA, USA), anti-AHR (1:1000; Cell Signaling Technology), and anti β-tubulin 
monoclonal antibody (1:1000; Sigma-Aldrich, MO, USA). The antigen–antibody com-
plexes were visualized using appropriate secondary antibodies and the ECL detection 
system by means of ChemiDoc imaging system (Bio-Rad Laboratories, Hercules, CA, 
USA) 
4.7. Immunofluorescence 
SK-Mel-28 were seeded (1 × 104 cells) in high D-glucose DMEM with 10% FBS onto 
LabTek Slides Chamber and incubated in a 5% CO2 atmosphere at 37 °C for 24 h. Then, a 
fresh medium with low serum concentration (1% FBS) was added, and cells were stimu-
lated with dex or IFN-γ for 3, 6, and 24 h. Double immunofluorescence analyses were 
performed on cells after fixation with cold acetone for 5 min. Nonspecific binding sites 
were blocked with 10 mg/mL bovine serum albumin in PBS for 1 h at room temperature 
with 0.2% triton X-100 (Sigma-Aldrich), then were treated with a primary antibody, i.e., 
monoclonal rabbit anti-human AhR (1: 100; Cell Signaling Technology), polyclonal rabbit 
anti-human IDO1 (1:200; abcam), or monoclonal anti human-TDO (1:200; Novus Biologi-
cals) overnight at 4 °C, then treated for 2 h at room temperature with a secondary goat 
anti-rabbit or anti-mouse antibodies conjugated with FITC AF488 (green fluorescence), all 
from Life Technology (Thermo Fisher Scientific). The signal was amplified with anti-FITC 
fluorescein/Oregon green antibody for 1.5 h (1:100; Invitrogen) at room temperature. The 
nuclei were labeled with Hoechst 33,342 (20 µg/mL; Sigma; blue fluorescence). Omission 
of primary antibodies was used as negative controls. The slides were mounted with Flu-
oromount and examined with Leica DC200 microscope digital color camera and Leica DC 
Viewer software. 
4.8. Gelatin Zymography 
MMP-2 and MMP-9 activity was assessed as gel zymography [57]. Starved cells were 
stimulated with 25 µM dex in the presence or the absence of 680C91 (40 µM) and epaca-
dostat (1 µM). After 24 h, the media were collected, clarified by centrifugation at 14,000× 
g RPM for 7 min, and subjected to electrophoresis onto 8% SDS-PAGE containing 1 mg/mL 
gelatin under non-denaturing conditions. Following electrophoresis, gels were washed 
with 2.5% Triton X-100 and incubated for 48 h at 37 °C in a 50 mM Tris buffer containing 
200 mM NaCl and 20 mM CaCl2, pH 7.4. Gels were then stained with 0.5% Coomassie 
brilliant blue R-250 in 10% acetic acid and 45% methanol and destained with 10% acetic 
acid and 45% methanol, all from Sigma-Aldrich. Gelatinase activity was then evaluated 
by quantitative densitometry. 
4.9. Materials 
The 680C91 ((E)-6-fluoro-3-[2-(3-pyridyl)vinyl]-1H-indole), 1-MT, a competitive in-
hibitor of IDO1, anti β-tubulin monoclonal antibody, TRI Reagent, and actinomycin-D 
were from Merck (KGaA, Darmstadt, Germany). Mouse monoclonal anti-TDO antibody 
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was from NovusBio (Bio-Techne, Minneapolis, MI, USA). high D-glucose DMEM, and 
PBS were from Euroclone S.p.A. (Pero, Milan, Italy). Epacadostat was from DivBioScience, 
Ulvenhout, The Netherlands. 
4.10. Statistical Evaluation 
Statistical analysis was performed with Prism software (GraphPad 5.02). Parametric 
data were reported as means ± SEM, and differences between groups were tested with 
ANOVA test (followed by Bonferroni’s and Dunnett’s Multiple Comparison Test) as ap-
propriate. Alpha value was set at 0.05. 
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